148 related articles for article (PubMed ID: 30517973)
1. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys.
Ogawa SI; Tsunenari Y; Kawai H; Yamazaki H
Biopharm Drug Dispos; 2019 Jan; 40(1):12-17. PubMed ID: 30517973
[TBL] [Abstract][Full Text] [Related]
2. Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver.
Ogawa SI; Uehara S; Tsunenari Y; Kawai H; Suemizu H; Yamazaki H
Xenobiotica; 2020 Jul; 50(7):769-775. PubMed ID: 31766940
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1.
Ogawa SI; Shimizu M; Kamiya Y; Uehara S; Suemizu H; Yamazaki H
Drug Metab Pharmacokinet; 2020 Aug; 35(4):354-360. PubMed ID: 32601018
[TBL] [Abstract][Full Text] [Related]
4. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
5. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
8. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
9. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.
Yamamoto Y; Takei K; Arulmozhiraja S; Sladek V; Matsuo N; Han SI; Matsuzaka T; Sekiya M; Tokiwa T; Shoji M; Shigeta Y; Nakagawa Y; Tokiwa H; Shimano H
Biochem Biophys Res Commun; 2018 May; 499(2):239-245. PubMed ID: 29567478
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
[TBL] [Abstract][Full Text] [Related]
11. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
12. Pemafibrate: First Global Approval.
Blair HA
Drugs; 2017 Oct; 77(16):1805-1810. PubMed ID: 28929345
[TBL] [Abstract][Full Text] [Related]
13. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
[TBL] [Abstract][Full Text] [Related]
14. Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.
Suto K; Fukuda D; Shinohara M; Ganbaatar B; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
J Atheroscler Thromb; 2021 Dec; 28(12):1349-1360. PubMed ID: 33775978
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
16. A validated LC-MS/MS method for the low-level determination of pemafibrate, a novel SPPARMα, in plasma.
Kobuchi S; Shigemura A; Ito Y; Sakaeda T
Bioanalysis; 2020 May; 12(10):683-692. PubMed ID: 32489112
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Ida S; Kaneko R; Murata K
Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
[TBL] [Abstract][Full Text] [Related]
18. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
[TBL] [Abstract][Full Text] [Related]
19. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C; Masuda D; Koseki M; Yamashita S
Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
[TBL] [Abstract][Full Text] [Related]
20. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]